INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
INmune Bio (NASDAQ: INMB) said it will present positive Phase 2 imaging results for XPro1595 in early Alzheimer’s at AAIC. The company reported statistically significant Week 24 treatment differences in white matter myelin integrity and concordant cortical microstructure changes, supporting selective soluble TNF inhibition target engagement. Poster details include longitudinal and subgroup analyses.
How this was made
The 30-second read
Why it matters
The new AAIC presentation emphasizes methodologically independent MRI endpoints (white matter myelin integrity via chi-separation and cortical microstructure via CDM) changing in the same direction, which is intended to strengthen the interpretation of treatment-related biology.
Market read
This is a conference catalyst with incremental efficacy-supporting imaging evidence at Week 24, likely to influence near-term sentiment and positioning ahead of the poster.
What to watch
Investors may focus on whether the biomarker enrichment strategy introduces selection bias, and whether subgroup and longitudinal analyses in the poster materially strengthen the topline claim.
Background
INmune Bio’s XPro1595 is a selective soluble TNF inhibition program in early Alzheimer’s, with prior topline Week 24 imaging biomarker results referenced as context.
Ticker impact
INmune Bio reports new Phase 2 AAIC-bound imaging data showing statistically significant Week 24 treatment effects for XPro in early Alzheimer’s.
Near-term sentiment tailwind for INMB into AAIC, with follow-through dependent on how investors weigh imaging biomarker strength versus clinical outcomes.
The article discloses fresh, conference-bound imaging analyses (not just a recap) and reiterates Week 24 statistical significance, but it does not provide new clinical endpoints, effect sizes, or safety details that would more directly re-rate risk.
Market effects
Reinforces investor appetite for neuroinflammation-targeting Alzheimer’s programs using advanced MRI biomarker readouts.
Limited direct regional impact; conference-driven sentiment may spill over to US-listed neurodegeneration biotech peers.
AAIC visibility can influence global biotech sentiment around imaging-biomarker strategies in early Alzheimer’s trials.
Counterpoint
Imaging biomarker concordance may not translate into cognitive or functional benefit, so the market may discount the signal without clinical endpoint data.
Key entities
- companyINmune Bio Inc.
NASDAQ-listed biotech presenting expanded Phase 2 imaging analyses for XPro1595 at AAIC.
- drug_programXPro1595
Dominant-negative TNF platform selectively neutralizing soluble TNF for early Alzheimer’s neuroinflammation.
- eventAAIC 2026
Alzheimer’s Association International Conference where the poster will be presented July 12-15, 2026.
